Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma

Cancer Research

Volumn 70, Issue 20, 2010, Pages 8199-8210

  Zhou, Limei ^a   Picard, Daniel ^a,b   Ra, Young Shin ^e   Li, Meihua ^a   Northcott, Paul A ^a,b   Hu, Yaqi ^b   Stearns, Duncan ^d   Hawkins, Cynthia ^a,b   Taylor, Michael D ^a   Rutka, James ^a   Der, Sandy D ^c   Huang, Annie ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; THROMBOSPONDIN 1;

ARTICLE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; RNA INTERFERENCE;

CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; CEREBELLAR NEOPLASMS; GENE SILENCING; GENES, MYC; GENES, REPORTER; HUMANS; MEDULLOBLASTOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNA, NEOPLASM; THROMBOSPONDIN 1;

EID: 78049276723     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4562     Document Type: Article

References (55)

1. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002;94:552-60.
2. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003;63:140-8. (Pubitemid 36070432)
3. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004;10:5482-93.
4. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52.
5. Badiali M, Pession A, Basso G, et al. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori 1991;77:118-21.
6. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-4.
7. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, anaplasia. J Neuropathol Exp Neurol 2004;63:441-9. (Pubitemid 38669665)
8. de Haas T, Hasselt N, Troost D, et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, CCNB1 expression. Clin Cancer Res 2008;14:4154-60.
9. Rutkowski S, von Bueren A, von Hoff K, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007;13:2651-7. (Pubitemid 46788032)
10. Cotterman R, Jin VX, Krig SR, et al. N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 2008;68:9654-62.
11. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006;66:673-81. (Pubitemid 43165929)
12. Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S. Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol 2008;116:383-90.
13. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 1993;72:233-45. (Pubitemid 23044938)
14. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation.Oncogene 1999;18:2916-24.
15. Mao DY, Watson JD, Yan PS, et al. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol 2003;13:882-6.
16. Staller P, Peukert K, Kiermaier A, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001;3:392-9. (Pubitemid 32288447)
17. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50.
18. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 2007;8:70-6. (Pubitemid 46043803)
19. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res 2002;84:81-154.
20. Pelengaris S, Khan M. The many faces of c-MYC. Arch Biochem Biophys 2003;416:129-36.
21. Landay M, Oster SK, Khosravi F, et al. Promotion of growth and apoptosis in c-myc nullizygous fibroblasts by other members of the myc oncoprotein family. Cell Death Differ 2000;7:697-705. (Pubitemid 30599250)
22. Huang A, Ho CS, Ponzielli R, et al. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells. Cancer Res 2005;65:5607-19. (Pubitemid 40911161)
23. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995;23:1686-90.
24. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG, Jr. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998;18:6316-24.
25. Wells J, Farnham PJ. Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods 2002;26:48-56. (Pubitemid 34969217)
26. CGI arrays. Available from: http://data.microarrays.ca/cpg/.
27. Heisler LE, Torti D, Boutros PC, et al. CpG island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res 2005;33:2952-61. (Pubitemid 41511234)
28. Myc Cancer Gene. Available from: http://www.myc-cancer-gene.org/.
29. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. In press 2010.
30. Page K, Li J, Zhou L, et al. Regulation of airway epithelial cell NF-κB-dependent gene expression by protein kinase Cδ. J Immunol 2003;170:5681-9. (Pubitemid 36617861)
31. Yang QW, Liu S, Tian Y, et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003;63:6299-310. (Pubitemid 37255177)
32. Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol 2003;13:376-85.
33. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997;8:1039-48. (Pubitemid 27433292)
34. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
35. Oster SK, Mao DY, Kennedy J, Penn LZ. Functional analysis of the N-terminal domain of the Myc oncoprotein. Oncogene 2003;22:1998-2010. (Pubitemid 36523637)
36. Gartel AL, Ye X, Goufman E, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 2001;98:4510-5. (Pubitemid 32295007)
37. Ou XM, Chen K, Shih JC. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A 2006;103:10923-8. (Pubitemid 44148396)
38. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27:1627-36.
39. Fukunaga-Johnson N, Lee JH, Sandler HM, Robertson P, McNeil E, Goldwein JW. Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa? Int J Radiat Oncol Biol Phys 1998;42:143-6.
40. Zeller KI, Zhao X, Lee CW, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 2006;103:17834-9.
41. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 2001;15:2069-82.
42. Testa A, Donati G, Yan P, et al. Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters. J Biol Chem 2005;280:13606-15.
43. Knoepfler PS. Myc goes global: new tricks for an old oncogene. Cancer Res 2007;67:5061-3.
44. Shen JC, Unoki M, Ythier D, et al. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin α1. Cancer Res 2007;67:2552-8.
45. Takahashi K, Nakanishi H, Miyahara M, et al. Nectin/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with afadin, a PDZ domain-containing protein. J Cell Biol 1999;145:539-49. (Pubitemid 29215718)
46. Escalante-Alcalde D, Hernandez L, Le Stunff H, et al. The lipid phosphatase LPP3 regulates extra-embryonic vasculogenesis and axis patterning. Development 2003;130:4623-37. (Pubitemid 37279415)
47. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-31. (Pubitemid 37443878)
48. Ngo CV, Gee M, Akhtar N, et al. An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ 2000;11:201-10. (Pubitemid 30211009)
49. Gilhuis HJ, van der Laak JA, Pomp J, Kappelle AC, Gijtenbeek JM, Wesseling P. Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes. Angiogenesis 2006;9:201-8.
50. Grotzer MA, Wiewrodt R, Janss AJ, et al. High microvessel density in primitive neuroectodermal brain tumors of childhood. Neuropediatrics 2001;32:75-9.
51. Tikhonenko AT, Black DJ, Linial ML. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem 1996;271:30741-7.
52. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-5. (Pubitemid 44325933)
53. Northcott PA, Fernandez LA, Hagan JP, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 2009;69:3249-55.
54. Janz A, Sevignani C, Kenyon K, Ngo CV, Thomas-Tikhonenko A. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. Nucleic Acids Res 2000;28:2268-75. (Pubitemid 30639360)
55. Yang Q, Tian Y, Liu S, et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007;67:1716-24. (Pubitemid 46383398)